Generate Investment Management Ltd Buys 259,265 Shares of Boston Scientific Corporation $BSX

Generate Investment Management Ltd increased its stake in Boston Scientific Corporation (NYSE:BSX) by 190.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 395,081 shares of the medical equipment provider’s stock after purchasing an additional 259,265 shares during the quarter. Boston Scientific comprises about 2.0% of Generate Investment Management Ltd’s holdings, making the stock its 14th largest position. Generate Investment Management Ltd’s holdings in Boston Scientific were worth $38,572,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in BSX. Brighton Jones LLC increased its position in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. Axiom Investors LLC DE grew its stake in Boston Scientific by 26.8% during the first quarter. Axiom Investors LLC DE now owns 4,759,258 shares of the medical equipment provider’s stock valued at $480,114,000 after acquiring an additional 1,006,828 shares in the last quarter. Trexquant Investment LP bought a new stake in Boston Scientific during the 1st quarter worth approximately $2,464,000. Quarry LP lifted its stake in Boston Scientific by 539.1% in the 1st quarter. Quarry LP now owns 1,732 shares of the medical equipment provider’s stock worth $175,000 after purchasing an additional 1,461 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC lifted its stake in Boston Scientific by 9.2% in the 1st quarter. Focus Partners Advisor Solutions LLC now owns 12,223 shares of the medical equipment provider’s stock worth $1,233,000 after purchasing an additional 1,034 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $95.98 on Wednesday. The firm has a market capitalization of $142.28 billion, a PE ratio of 51.32, a price-to-earnings-growth ratio of 1.93 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The business’s 50-day moving average price is $98.36 and its 200-day moving average price is $101.05.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 earnings per share. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total transaction of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 93,095 shares of company stock valued at $9,305,450. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on BSX shares. BTIG Research reaffirmed a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a report on Friday, November 21st. Robert W. Baird boosted their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company upped their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $124.85.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.